Precigen, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Helen Sabzevari
- Full Time Employees
- 160
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 20374 Seneca Meadows Parkway Germantown MD United States of America 20876
- IPO Date
- Aug 8, 2013
- CIK
- 0001356090
- Website
- precigen.com
- Similar Companies
- Business
- Precigen, Inc. (Nasdaq: PGEN) is a clinical-stage biopharmaceutical company that develops gene and cell therapies using proprietary precision technologies to target diseases in immuno-oncology, autoimmune disorders, and infectious diseases; its core platforms include the AdenoVerse immunotherapy platform, which employs proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens, and the UltraCAR-T platform, which provides controllable chimeric antigen receptor T-cell therapies for hematological malignancies and solid tumors. The company offers PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved AdenoVerse gene therapy for recurrent respiratory papillomatosis (RRP) in adults; additional pipeline candidates such as PRGN-2009 in combination with pembrolizumab for HPV-associated cancers, PRGN-3005 for ovarian cancer, PRGN-3006 for acute myeloid leukemia and myelodysplastic syndromes, and PRGN-3007 for hematological and solid tumors; and services through its Exemplar subsidiary, which develops research models for healthcare applications including the UltraPorator electroporation device. Founded in 1998 and headquartered in Germantown, Maryland, Precigen operates primarily in the United States with a focus on advancing therapies from discovery through commercialization. Recent developments include the FDA approval of PAPZIMEOS in 2025, a $125 million non-dilutive credit facility with Pharmakon Advisors in September 2025 featuring a $100 million initial tranche to support U.S. commercialization of PAPZIMEOS and international expansion, and a $79 million private placement of preferred stock in December 2024 extending cash runway into 2026.
Company News
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Precigen (NASDAQ:PGEN) Hits New 1-Year High – Time to Buy?
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Head-To-Head Comparison: Precigen (NASDAQ:PGEN) and Celldex Therapeutics (NASDAQ:CLDX)
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Legal & General Group Plc Takes $730,000 Position in Precigen, Inc. $PGEN
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
5 Biotech Stocks Worth Adding to Your Portfolio Now
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
Reasons Why Investors Should Consider Betting on PGEN Stock
Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice
Precigen: Has To Grow Into Its Valuation
Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement
Arrowstreet Capital Limited Partnership Acquires Shares of 395,695 Precigen, Inc. $PGEN
Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript
Precigen Q2 Earnings Call Highlights
Precigen, Inc. (PGEN) Q2 Earnings and Revenues Surpass Estimates
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4